Cargando…

Pancreatic islet organoids-on-a-chip: how far have we gone?

Diabetes mellitus (DM) is a disease caused by dysfunction or disruption of pancreatic islets. The advent and development of microfluidic organoids-on-a-chip platforms have facilitated reproduce of complex and dynamic environment for tissue or organ development and complex disease processes. For the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Jiaxiang, Meng, Hao, Lin, Jingfang, Ji, Wei, Xu, Tao, Liu, Huisheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238112/
https://www.ncbi.nlm.nih.gov/pubmed/35764957
http://dx.doi.org/10.1186/s12951-022-01518-2
_version_ 1784736957464576000
author Yin, Jiaxiang
Meng, Hao
Lin, Jingfang
Ji, Wei
Xu, Tao
Liu, Huisheng
author_facet Yin, Jiaxiang
Meng, Hao
Lin, Jingfang
Ji, Wei
Xu, Tao
Liu, Huisheng
author_sort Yin, Jiaxiang
collection PubMed
description Diabetes mellitus (DM) is a disease caused by dysfunction or disruption of pancreatic islets. The advent and development of microfluidic organoids-on-a-chip platforms have facilitated reproduce of complex and dynamic environment for tissue or organ development and complex disease processes. For the research and treatment of DM, the platforms have been widely used to investigate the physiology and pathophysiology of islets. In this review, we first highlight how pancreatic islet organoids-on-a-chip have improved the reproducibility of stem cell differentiation and organoid culture. We further discuss the efficiency of microfluidics in the functional evaluation of pancreatic islet organoids, such as single-islet-sensitivity detection, long-term real-time monitoring, and automatic glucose adjustment to provide relevant stimulation. Then, we present the applications of islet-on-a-chip technology in disease modeling, drug screening and cell replacement therapy. Finally, we summarize the development and challenges of islet-on-a-chip and discuss the prospects of future research. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-9238112
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92381122022-06-29 Pancreatic islet organoids-on-a-chip: how far have we gone? Yin, Jiaxiang Meng, Hao Lin, Jingfang Ji, Wei Xu, Tao Liu, Huisheng J Nanobiotechnology Review Diabetes mellitus (DM) is a disease caused by dysfunction or disruption of pancreatic islets. The advent and development of microfluidic organoids-on-a-chip platforms have facilitated reproduce of complex and dynamic environment for tissue or organ development and complex disease processes. For the research and treatment of DM, the platforms have been widely used to investigate the physiology and pathophysiology of islets. In this review, we first highlight how pancreatic islet organoids-on-a-chip have improved the reproducibility of stem cell differentiation and organoid culture. We further discuss the efficiency of microfluidics in the functional evaluation of pancreatic islet organoids, such as single-islet-sensitivity detection, long-term real-time monitoring, and automatic glucose adjustment to provide relevant stimulation. Then, we present the applications of islet-on-a-chip technology in disease modeling, drug screening and cell replacement therapy. Finally, we summarize the development and challenges of islet-on-a-chip and discuss the prospects of future research. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2022-06-28 /pmc/articles/PMC9238112/ /pubmed/35764957 http://dx.doi.org/10.1186/s12951-022-01518-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yin, Jiaxiang
Meng, Hao
Lin, Jingfang
Ji, Wei
Xu, Tao
Liu, Huisheng
Pancreatic islet organoids-on-a-chip: how far have we gone?
title Pancreatic islet organoids-on-a-chip: how far have we gone?
title_full Pancreatic islet organoids-on-a-chip: how far have we gone?
title_fullStr Pancreatic islet organoids-on-a-chip: how far have we gone?
title_full_unstemmed Pancreatic islet organoids-on-a-chip: how far have we gone?
title_short Pancreatic islet organoids-on-a-chip: how far have we gone?
title_sort pancreatic islet organoids-on-a-chip: how far have we gone?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238112/
https://www.ncbi.nlm.nih.gov/pubmed/35764957
http://dx.doi.org/10.1186/s12951-022-01518-2
work_keys_str_mv AT yinjiaxiang pancreaticisletorganoidsonachiphowfarhavewegone
AT menghao pancreaticisletorganoidsonachiphowfarhavewegone
AT linjingfang pancreaticisletorganoidsonachiphowfarhavewegone
AT jiwei pancreaticisletorganoidsonachiphowfarhavewegone
AT xutao pancreaticisletorganoidsonachiphowfarhavewegone
AT liuhuisheng pancreaticisletorganoidsonachiphowfarhavewegone